New drug duo aims to boost immune System's fight against tough cancer
NCT ID NCT05980000
Summary
This study is testing if adding a drug called ramucirumab to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has returned or spread. The goal is to see if the combination helps shrink tumors and control the cancer for longer. The trial is for adults with this specific cancer who have not yet received drug treatment for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HEAD AND NECK CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.